MedPath

Liver Transplantation for Non-Resectable Colorectal Liver Metastasis

Not Applicable
Recruiting
Conditions
Colorectal Cancer
Liver Metastasis Colon Cancer
Interventions
Procedure: Liver Transplantation
Registration Number
NCT05185245
Lead Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Brief Summary

The study aims to evaluate the efficacy of liver transplantation in the context of non-resectable colorectal liver metastasis. The primary endpoint is the overall survival in this group of patients while the secondary endpoint is the disease-free survival.

Patients included in this protocol will be evaluated either for whole or partial liver transplantation from deceased or living donors.

Type of different transplantations proposed are as follows:

1. Whole liver graft or partial liver (split) from a deceased donor

2. Partial liver graft retrieved from a deceased donor and orthotopically implanted after having performed a left hepatectomy in the recipient.

3. Partial liver graft retrieved from a deceased donor and heterotopically implanted if total hepatectomy can not be performed.

4. Partial liver graft retrieved from a living donor and orthotopically implanted after having performed total hepatectomy.

5. Partial liver graft retrieved from a living donor and orthotopically implanted after having after having performed a left hepatectomy in the recipient.

6. Partial liver graft retrieved from a living donor and heterotopically implanted if total hepatectomy can not be performed.

In cases 2-3-5-6 total hepatectomy of native liver can be secondarily performed after having achieved a proper graft hypertrophy in order to avoid a small for size syndrome

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Primary tumor resected according to standard oncological practice, p≤T4a, R0 resection
  • Colorectal liver metastasis considered as non-resectable either up-front or after previous hepatic resections
  • No local recurrence of primary colon cancer confirmed by Positron Emission Tomography, Computed Tomography and colonoscopy
  • No extra-hepatic metastatic disease confirmed by Positron Emission Tomography and Computed Tomography
  • Good performance status Eastern Cooperative Oncology Group 0 or 1
  • Neutrophils > 1.000
  • Patients who received at least one line of chemotherapy for at least 3 months with partial response or stable disease according to modified Response Evaluation Criteria in Solid Tumours
  • Carcino-Embryonic Antigen < 80 µg/L or reduction of ≥ 50% of highest Carcino-Embryonic Antigen level observed
  • Written informed consent
  • No other contraindications to liver transplantation
Exclusion Criteria
  • Presence of other malignancies
  • Local recurrence of primary tumor
  • Extra-hepatic metastatic disease
  • Patients who did not receive any neoadjuvant or adjuvant therapy
  • Palliative resection of primary tumor
  • Any other reason, according to the investigators, that could be a contraindication to protocol enrollment

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Liver TransplantationLiver Transplantation-
Primary Outcome Measures
NameTimeMethod
Overall Survival5 years
Secondary Outcome Measures
NameTimeMethod
Disease-Free Survival5 years

Trial Locations

Locations (1)

IRCCS Azienda Ospedaliero - Universitaria di Bologna

🇮🇹

Bologna, Italy

© Copyright 2025. All Rights Reserved by MedPath